Mitoxantrone hydrochloride liposome (CSPC ZhongQi)

盐酸米托蒽醌脂质体（石药集团）

Report date: 2026/05/09 20:00:18

Base Information

Drug NameMitoxantrone hydrochloride liposome (CSPC ZhongQi)
Drug Alias NameHE071 (米托蒽醌脂质体)Mitoxantrone Hydrochloride Liposome Injection (CSPC ZhongQi)Pegylated liposomal mitoxantrone (CSPC ZhongQi)多恩达Duoenda +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHepatitis C virus serine protease, NS3/NS4A inhibitorsProto-oncogene serine/threonine-protein kinase Pim-1 inhibitorsTopoisomerase II inhibitors
TargetsTopoisomerase IIProto-oncogene serine/threonine-protein kinase Pim-1Hepatitis C virus serine protease, NS3/NS4A
Therapy Area/IndicationsSolid tumoursNeuromyelitis OpticaMultiple Sclerosis +[23] 
Global Approved IndicationsLymphoma, T-Cell, Peripheral
Approved Indications in ChinaLymphoma, T-Cell, Peripheral
Original Approved Country/TerritoryMainland China
Original Approved Date2022/01/07
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesCSPC Pharmaceutical Group Ltd
China Registration ClassN/A

Develop Information

Active CompaniesCspc Zhongqi Pharmaceutical Technology (Tianjin) Co LtdSun Yat-Sen UniversityCspc Ouyi Pharmaceutical Co Ltd +[5] 
Inactive CompaniesN/A
Active IndicationsSolid tumoursNeuromyelitis OpticaHead and Neck Neoplasms +[14] 
Inactive IndicationsMultiple SclerosisSmall Cell Lung CarcinomaOvarian Neoplasms +[9] 

Other Information

ATC CodeN/A
Related LinksN/A